Patient-specific and healthcare real-world costs of atrial fibrillation in individuals treated with direct oral anticoagulant agents or warfarin

BACKGROUND: Anticoagulant therapies are used to prevent atrial fibrillation-related strokes, with warfarin and direct oral anticoagulant (DOAC) the most common. In this study, we incorporate direct health care costs, drug costs, travel costs, and lost working and leisure time costs to estimate the t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pyykönen, Mikko, Linna, Miika, Tykkyläinen, Markku, Delmelle, Eric, Laatikainen, Tiina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641166/
https://www.ncbi.nlm.nih.gov/pubmed/34856979
http://dx.doi.org/10.1186/s12913-021-07125-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641166/
https://www.ncbi.nlm.nih.gov/pubmed/34856979
http://dx.doi.org/10.1186/s12913-021-07125-5

Ejemplares similares